The Korean Journal of Internal Medicine

Search

Close

Original Article
Korean J Med. 2010;78(5):645-649.
동시적 항암화학방사선요법 시행 후 수술에 성공한 진행성 흉선암종 1예
임현우, 이명준, 박정호, 박주호, 이선영, 전현정, 조도연
Division of Allergy, Asthma and Clinical Immunology, Department of Internal Medicine, Chonnnam National University Medical School, Gwangju, Korea
A case of advanced thymic carcinoma that was resected after concurrent chemoradiotherapy
Hyun Woo Lim, Myung Jun Lee, Jeong Ho Park, Joo Ho Park, Sun Young Lee, Hyun Jung Jun, Do Yeun Cho
전남대학교 의과대학 알레르기내과


Abstract
Thymic carcinoma is a rare, but aggressive, tumor that often metastasizes to regional lymph nodes and distant sites and often has a poor prognosis. Although the efficacy of induction therapy in thymic carcinoma is unclear, we report the clinical course of a patient who underwent complete surgical resection after effective induction chemoradiotherapy. A 66-year-old man was diagnosed with a poorly differentiated thymic carcinoma (Masaoka stage III). The tumor was considered unresectable due to sternal invasion and surrounding fat infiltration. Two cycles of chemotherapy, consisting of paclitaxel (180 mg/m2 on D1) and cisplatin (80 mg/m2 on D1) combined with mediastinal radiotherapy (total 50 Gy) were performed concurrently; the mass decreased to a resectable size. Subsequently, he received adjuvant chemotherapy and adjuvant radiation therapy. He is currently alive and ambulatory and has remained disease-free for 19 months. This case demonstrates that induction chemoradiotherapy with paclitaxel and cisplatin may be tolerated and useful for patients with locally advanced thymic carcinoma. (Korean J Med 78:645-649, 2010)

Keywords :Thymic carcinoma, Paclitaxel, Cisplatin, Neoadjuvant chemoradiotherapy, Surgery
hanmi ckdpharm. AMGEN
Memo patch yungjin daewoongbio

Go to Top